Quantitative analysis of Annexin V demonstrated that there was a significant increase in protein expression among mucinous CRC pre-FOLFOX treatment compared with post-FOLFOX-treated cells (p = 0.0001) and also post-FOLFOX-treated CRC NOS (well differentiated adenocarcinoma, p = 0.0046). The gene discussed is ANXA5; the disease is adenocarcinoma.